Visit COVID-19 resources

[Skip to Content]

Uncategorised

RCOphth host London Assembly launch of report into eye health and sight loss in London

Dec 08
2017

The RCOphth was delighted to offer our premises in Stephenson Way to the London Assembly (LA) to launch their Health Committee report ‘Eye Health – preventing sight loss in London’ on 5 December 2017. Along with a number of other eye sector organisations, patients and patient groups, we contributed to the final report findings.  Mike Burdon and

  • 8 December 2017

Eye Care in the Intensive Care Unit (ICU)

Nov 29
2017

Produced in collaboration with the Intensive Care Society, the Eye Care in Intensive Care Unit guidance provides advice for clinical staff involved in eye care in the ICU. It is primarily intended to help non-ophthalmic ICU staff to: protect the eye in vulnerable patients, thus preventing ICU-related eye problems identify disease affecting the eye in

  • 29 November 2017

NEW Defined Guidance for the use of Serum Eye Drops

Nov 29
2017

Ocular Surface Disease with dry eye is a global public-health problem with significant impact on quality of life. Serum Eye Drops (SED) contain many nutritional factors that aid therapeutics. Across the NHS there is variation in practice, inequality of access to SED service and no regulated monitoring of outcome. This guideline sets out defined guidance

  • 29 November 2017

RCOphth and NIHR launch Researcher of the Year Awards 2018

Nov 29
2017

The Royal College of Ophthalmologists and The National Institute for Health Research are pleased to announce the opening for applications of the 2018 RCOphth / NIHR Researcher of the Year awards. Applications are sought from Members and Fellows of the College who are engaged in clinical research in the course of their NHS duties. Clinical

  • 29 November 2017

RCOphth collaborate with the BMJ on latest Avastin editorial

Nov 02
2017

Have you read the BMJ editorial ‘Are the odds shifting against pharma in the fight for cheaper treatment for macular degeneration?’  We collaborated with the BMJ journalist to support the overall message of a much needed review of the ‘off-label’ status of Bevacizumab (Avastin), particularly in relation to the most recent news from the EU

  • 2 November 2017